Navigation Links
Cowen Group Announces Promotions in Health Care Investment Banking
Date:3/4/2010

Mr. Reikes stated, "I look forward to transitioning into this developmental role at Cowen and believe that Declan is uniquely positioned to carry on the health care group's activities, given his long tenure in the health care banking field and experience at Cowen.  I have every confidence that our franchise and momentum will be enhanced under his leadership."  

About Cowen Group, Inc.

Cowen Group, Inc. is a leading diversified financial services firm providing alternative investment management, investment banking, research, and sales and trading services through its business units, Ramius and Cowen and Company.  Its alternative investment management products include hedge funds, fund of funds, real estate funds, healthcare royalty funds, cash management and commodity trading funds, offered primarily under the Ramius name.  Cowen and Company offers industry focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors.  Founded in 1918, the firm is headquartered in New York and has offices located in major financial centers around the world.

<
'/>"/>
SOURCE Cowen Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Centene Corporation to Present at Cowen and Company Annual Health Care Conference
2. Labopharm to present at Cowen 30th Annual Health Care Conference
3. Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
4. Cowen Announces Hiring of Don Munoz to Lead Medical Technology Practice; 5th Senior-Level Addition to Cowens Health Care Franchise in 2009
5. InterMune to Present at Cowen Health Care Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
7. Palatin Technologies to Present at Cowen Annual Health Care Conference on March 19, 2009
8. MAP Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
9. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
10. NuVasive to Present at Cowen and Company 29th Annual Healthcare Conference
11. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... Metamora, Michigan (PRWEB) May 30, 2015 ... procedure to lighten or stop periods, without the ... This procedure can reduce or stop menstrual bleeding and ... the uterus (the part that causes the bleeding), with ... million women suffer from heavy menstrual bleeding. Many ...
(Date:5/30/2015)... Diego, CA (PRWEB) May 30, 2015 ... is the lack of local healthcare options available. Often, ... to adequate healthcare. For those in rural areas feeling ... simply without health insurance or tired of paying high ... new E-consults, connecting patients with licensed physicians via the ...
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... EHO offers a suite of online applications ... the ability to manage their drug-spend for the lowest ... EHO has been able to compete with the big ... survive among the giants of the industry. Since EHO ... ago, it has simplified the way hospices can monitor ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2
... Michigan Comprehensive Cancer Center have identified a potential new way ... cells in a tumor that fuel its growth and spread. ... by a type of cell derived from bone marrow, called ... marrow to the cancer and create a "niche" for the ...
... Controlling blood pressure is not only a medical challenge, ... required to strictly adhere to a treatment plan that ... the ideas of wellness and health are also powerful ... This is especially true in the African American ...
... 2011 - A recent study by Merikangas and colleagues ... Journal of the American Academy of Child and Adolescent ... that are affected with severely impairing mental disorders ever ... found that approximately one third of adolescents with any ...
... January 18, 2011 Heart disease is the leading cause ... States. But heart disease is more than just one disease; ... heart attack, high blood pressure, diabetes or other causes. In ... accumulation in heart cells. Obesity and high-fat diets are major ...
... the World Health Organisation (WHO), an estimated 322,000 deaths globally ... in many of these cases death could have been avoided ... major burn patients have insufficient skin left to graft on ... literally to be grown from the patient,s own skin cells. ...
... By Kathleen Doheny HealthDay Reporter , ... creams that promise "broad-spectrum" sun protection actually measure up, ... daytime moisturizers claiming to provide broad-spectrum protection from the ... reliable protection from harmful UV-A rays, which can penetrate ...
Cached Medicine News:Health News:U-M researchers find indirect path to attack breast cancer stem cells 2Health News:Storytelling may help control blood pressure in African-Americans 2Health News:Adolescents with severe mental disorders have never received treatment 2Health News:A different path to fat-related heart disease 2Health News:Nanotech medicine 2Health News:Nanotech medicine 3Health News:Nanotech medicine 4Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 2Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 3
(Date:5/29/2015)... and MENLO PARK, Calif. , ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... proven cancer therapies in new orphan drug indications, ... Association of Cancer Research (AACR) Advances in Brain ... its lead product candidate VAL-083 (dianhydrogalactitol) ...
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/28/2015)... -- Eli Lilly and Company (NYSE: LLY ) announced today ... for up to $1.6 billion aggregate principal amount of certain ... who tendered, and did not validly withdraw, their notes on ... time, on May 27, 2015 (the early tender date), ... to receive the total consideration. The total consideration for each ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... Amgen (Nasdaq: AMGN ) reported revenue unchanged ... $3,812 million for the third quarter of 2009. ... the third quarter of 2010 compared to $1,518 million for ... income was driven by unusually low research and development (R&D) ...
... 25 See video from Novartis: ... New Phase III data indicate that Menveo® (Meningococcal ... demonstrated robust immunogenicity in infants potentially offering protection ... 3. These data were presented during an oral ...
Cached Medicine Technology:Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 2Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 3Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 4Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 5Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 6Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 7Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 8Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 9Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 10Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 11Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 12Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 13Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 14Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 15
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Medicine Products: